Xenetic Biosciences Inc(XBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 4:02 PM ET (Korea 11/4 06:02)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.19 | Insider Own | 15.7% | Shs Outstand | 2.3M | Perf Week | 14% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.0M | Perf Month | -5.45% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 6.49% | Short Float | 0.55% | Perf Quarter | -29.73% |
| Income | -0.00B | P/S | 1.5 | EPS this Y | - | Inst Trans | -19.54% | Short Ratio | 0.12 | Perf Half Y | -32.69% |
| Sales | 0.00B | P/B | 0.8 | EPS next 5Y | - | ROA | -40.17% | Short Interest | 0.01M | Perf YTD | -4.15% |
| Book/sh | 2.59 | P/C | 0.75 | EPS past 3/5Y | 30.07% 37.89% | ROE | -47.04% | 52W High | -57.89% ($4.94) | Perf Year | -33.33% |
| Cash/sh | 2.76 | P/FCF | - | Sales past 3/5Y | 20.36% 46.78% | ROIC | -40.76% | 52W Low | 31.64% ($1.58) | Perf 3Y | -36% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 40.59% | Gross Margin | - | Volatility(W/M) | 10.48% 7.78% | Perf 5Y | -88.63% |
| Dividend TTM | - | EV/Sales | -0.49 | Sales Y/Y TTM | 33.3% | Oper. Margin | -81.01% | ATR (14) | 0.2 | Perf 10Y | -99.57% |
| Dividend Ex-Date | - | Quick Ratio | 7.43 | EPS Q/Q | 9.27% | Profit Margin | -75.91% | RSI (14) | 44.88 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.43 | Sales Q/Q | 11.99% | SMA20 | 2.81% ($2.02) | Beta | 2.35 | Target Price | $2.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/7 | SMA50 | -25.29% ($2.78) | Rel Volume | 0.13 | Prev Close | $2.06 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -26.76% ($2.84) | Avg Volume(3M) | 0.09M | Price | $2.08 |
| IPO | 2012/6/19 | Option/Short | No/Yes | Trades | 162 | Volume | 11,457 | Change | 0.97% |
🧬 Genetic Biosciences (GBS) is a US micro-cap biotech focused on developing immuno-oncology therapies. Its core asset is a DNase platform that targets neutrophil extracellular traps (NETs), and the company is currently validating the combination effects with CAR-T and conventional anticancer agents at the clinical stage.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded less than usual. That is 13% of its average volume.
XBIO has a sound balance sheet but weak earning power
Of every $100 in sales, $81.01 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $150. Peers typically go for $946.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -88.6%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 6.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #544 of 597 in the industry
Based on market cap of $5M.
IMNN#542 Imunon Inc $5M PER - 
CANF#543 Can-Fite Biopharma Ltd ADR $5M PER - XBIO#544 Xenetic Biosciences Inc $5M PER - 
PULM#545 Pulmatrix Inc $5M PER - 
CDIO#546 Cardio Diagnostics Holdings Inc $5M PER - 
FAQ
What kind of company is XBIO?
XBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of XBIO?
The market cap of XBIO is approximately $5M, ranking 5,624 within its sector.
What is the 52-week high and low for XBIO?
XBIO has recorded a 52-week high of $4.94 and a low of $1.58.
